Table 1.
Anti‐PCSK9 Therapeutic Approaches
| Mechanism of Action | Class | Agent | Company | Phase |
|---|---|---|---|---|
| PCSK9 binding | ||||
| Human monoclonal antibody | Alirocumab (REGN727/SAR236553) | Regeneron/Sanofi | Approved in USA and EU | |
| Human monoclonal antibody | Evolocumab (AMG145) | Amgen | Approved in USA and EU | |
| Humanized monoclonal antibody | Bococizumab (PF‐04950615) | Pfizer | 3 | |
| Human monoclonal antibody | LY3015014 | Eli Lilly | 2 | |
| Modified binding protein | Adnectin (BMS962476) | BMS/Adnexus | 1 | |
| Small‐molecule inhibitor | SX‐PCK9 | Serometrix | Preclinical | |
| PCSK9 synthesis | ||||
| RNA interference | ALN‐PCSsc | Alnylam/The Medicines Company | 1 | |
PCSK9, proprotein convertase subtilisin/kexin type 9.